XTL Biopharmaceuticals Ltd. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2016. XTL reported an operating loss for the quarter ended September 30, 2016 of $300,000 compared with $396,000 for the same period in 2015. The company reported a total comprehensive loss for the quarter ended September 30, 2016 of $279,000, or $0.001 per share, compared to $443,000 or $0.002 per share, in the same period in 2015. Loss from continuing operations was $286,000 against $443,000 a year ago. For the nine-month period ended September 30, 2016 XTL reported an operating loss of $1,368,000 as compared to $1,253,000 in the first nine months of the prior year. For the nine months ended September 30, 2016 XTL reported a total net loss of $1,222,000 or $0.005 per share, compared to $1,946,000 or $0.008 per share, in the first nine months of 2015. Total net loss in the first nine months of 2015 included a loss from discontinued operations of $460,000, or $0.002 per share. Loss from continuing operations was $1,340,000 against $1,486,000 a year ago.